INmune Bio Inc
INMB
View Detailed Chart
1.510USD
+0.090+6.34%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
40.14MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+6.34%
5 Days
-5.03%
1 Month
-3.21%
6 Months
-45.29%
Year to Date
-3.21%
1 Year
-84.59%
View Detailed Chart
TradingKey Stock Score of INmune Bio Inc
Currency: USD Updated: 2026-02-06Key Insights
INmune Bio Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 126 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.25.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
INmune Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
INmune Bio Inc Highlights
StrengthsRisks
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
Growing
The company is in a growing phase, with the latest annual income totaling USD 14.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 14.00K.
Overvalued
The company’s latest PE is -0.73, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 4.63M shares, decreasing 40.75% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 957.85K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 1.74.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
5.250
Target Price
+269.72%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
INmune Bio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
INmune Bio Inc Info
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
Ticker SymbolINMB
CompanyINmune Bio Inc
CEOMoss (David J)
Websitehttps://www.inmunebio.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
70650.780
+680.650 (+0.97%)
282.580
+22.390 (+8.61%)
2092.510
+40.780 (+1.99%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
